Clinical Trials Logo

Filter by:
NCT ID: NCT01090492 Completed - Clinical trials for Peripheral Vascular Disease

PF-00489791 For The Treatment Of Raynaud's

Start date: August 4, 2010
Phase: Phase 2
Study type: Interventional

The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.

NCT ID: NCT01090427 Completed - Psoriasis Clinical Trials

A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)

Start date: May 2010
Phase: Phase 3
Study type: Interventional

This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients with moderate to severe psoriasis.

NCT ID: NCT01090362 Completed - Atrial Fibrillation Clinical Trials

Global Anticoagulant Registry in the Field

GARFIELD-AF
Start date: December 21, 2009
Phase:
Study type: Observational

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF Registry) is a non-interventional, observational study that characterized a global population of non-valvular atrial fibrillation patients. The registry was used to document global baseline characteristics, current treatment strategies and outcome measures. Characterisation of a number of AF sub-populations was also completed. GARFIELD-AF is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).

NCT ID: NCT01089556 Completed - Clinical trials for Diabetic Neuropathy, Painful

A Study in Painful Diabetic Neuropathy

COMBO-DN
Start date: March 2010
Phase: Phase 3
Study type: Interventional

This study will investigate the efficacy of a combination treatment of duloxetine + pregabalin compared with the maximal dose of each drug in monotherapy, in patients with diabetic peripheral neuropathic pain (DPNP) who have not responded to the standard recommended dose of either drug. It will provide an answer to a common clinical question, namely, is it better to increase the dose of the current monotherapy or to combine both treatments early on, in patients who do not respond to standard doses of duloxetine or pregabalin.

NCT ID: NCT01089335 Completed - Thyroid Cancer Clinical Trials

Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia

SNTC
Start date: March 2010
Phase:
Study type: Observational

The standard surgical treatment for highly differentiated papillary thyroid cancer > 10 mm according to recent national and international guidelines, is total thyroidectomy and central lymphnode clearance, and for patients with cytology indicating thyroid neoplasia of unclear malignant potential hemithyroidectomy on the side of the tumour. The study investigates if the sentinel lymphnode (SN) - Reliably (with high sensitivity and specificity), can predict the pathological findings of the lymphnodes in the central compartment in patients with highly differentiated papillary thyroid cancer - Is useful to aid in the final diagnosis and staging of thyroid neoplasias of unclear malignant potential, and could be used to select patients for further central lymphnode revision.

NCT ID: NCT01088672 Completed - Ischemic Stroke Clinical Trials

Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)

TREVO
Start date: February 2010
Phase: Phase 4
Study type: Interventional

To determine the revascularization rate of the CE-marked Trevo device in large vessel occlusions in ischemic stroke patients. - Revascularization, defined as at least TICI 2a in the vascular territory treated at end of the neuro interventional procedure.

NCT ID: NCT01088152 Recruiting - Counseling Clinical Trials

Celiac Disease School for Women Living on a Gluten-free Diet

CDST
Start date: August 2008
Phase: N/A
Study type: Interventional

Swedish celiac disease women living on a gluten-free diet for years report poorer subjective health and more bowel complaints than Swedish women of same age in general population. The investigators hypothesis is that the women participating in an education programme based on problem based learning will show higher degree of perceived health than the women receiving usual care.

NCT ID: NCT01087619 Active, not recruiting - Clinical trials for Primary Hyperparathyroidism

Surgery for Primary Hyperparathyroidism (pHPT) in Patients Older Than 65 Years Compared With Follow-up

Start date: August 2010
Phase: N/A
Study type: Interventional

General consensus and contemporary guidelines, recommend surgery for primary hyperparathyroidism (pHPT)for all patients below the age of 50, for patients with pronounced hypercalcemia and for patients with organ complications to the disease (osteoporosis and decreased renal function). The purpose of this study is to determine if surgery for pHPT, is appropriate for patients with moderate to mild hypercalcemia older than 65 years of age. The hypothesis of the study is that surgery for pHPT in patients older than 65 years of age, and with mild hypercalcemia, will increase bone density and hence decrease future risk for fragility fractures compared to patients with follow-up only.

NCT ID: NCT01087593 Terminated - Fibromyalgia Clinical Trials

Estrogens Effect on Pain in Postmenopausal Women Suffering of Fibromyalgia

Start date: August 2001
Phase: N/A
Study type: Interventional

In order to evaluate the potential effects of estrogen treatment in postmenopausal women with fibromyalgia, the investigators used quantitative sensory tests before and after eight weeks of estrogen treatment as compared with placebo treatment.

NCT ID: NCT01087502 Completed - Clinical trials for Diabetes Mellitus, Type 2

Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

Start date: March 2010
Phase: Phase 3
Study type: Interventional

The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given over 12 weeks in drug naive or previously treated type 2 diabetic patients with moderate to severe renal impairment and insufficient glycaemic control. In addition safety in this patient population with longer term (40 week) treatment in comparison to sulfonylurea drug (glimepiride).